Humacyte (HUMA) to Release Quarterly Earnings on Friday

Humacyte (NASDAQ:HUMA - Get Free Report) is set to announce its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Stock Performance

Shares of Humacyte stock traded down $0.17 during trading on Thursday, hitting $5.26. 2,525,306 shares of the company's stock traded hands, compared to its average volume of 2,346,292. The business has a 50-day simple moving average of $5.49 and a 200-day simple moving average of $6.12. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The stock has a market capitalization of $627.79 million, a P/E ratio of -4.18 and a beta of 1.47. Humacyte has a 1 year low of $2.08 and a 1 year high of $9.97.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Benchmark restated a "buy" rating and issued a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. BTIG Research reiterated a "buy" rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. TD Cowen reiterated a "buy" rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. Finally, Piper Sandler set a $6.00 target price on Humacyte and gave the stock a "neutral" rating in a report on Friday, October 18th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $11.00.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now directly owns 3,677,262 shares of the company's stock, valued at $23,350,613.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the business's stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares of the company's stock, valued at $23,350,613.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock worth $6,869,996 over the last three months. 11.20% of the stock is owned by insiders.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.